3 hours ago
1
mohd izzuan
Verastem (NASDAQ:VSTM) shares added ~22% on Friday after the oncology-focused biotech reported better-than-expected financials for Q2 2025 as its newly approved ovarian cancer therapy, Avmapki Fakzynja Co-pack, was off to a strong commercial launch.
Needham, Massachusetts-based Verastem (NASDAQ:VSTM) rolled
English (US) ·